Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AK117 + paclitaxel
- Development stage
- Phase 2
- Lead developer
- Akeso
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
**AK117 + paclitaxel** is an experimental combination regimen under clinical investigation primarily for the treatment of advanced cancers (notably metastatic pancreatic cancer). **AK117** is a monoclonal antibody targeting CD47, an immune checkpoint protein often overexpressed on cancer cells that inhibits phagocytosis by binding to SIRPα on macrophages; by blocking this interaction, AK117 promotes anti-tumor immunity. **Paclitaxel** is a well-established chemotherapeutic agent that stabilizes microtubules and inhibits their depolymerization, thereby disrupting mitosis and promoting apoptosis in dividing cells. The combination aims to synergize cytotoxic tumor cell killing by paclitaxel with immune-mediated clearance mediated by AK117’s checkpoint inhibition.
- Other names
- AK117AK-117AK 117paclitaxelTaxol
02
Targets
CD47 (Cluster of Differentiation 47)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on AK117 + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AK117 + paclitaxel.